Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Cell Therapy
 More »

  • Pharma Touting Phase II/III Wins in Run-Up to ASCO
    of patients with advanced non-small-cell-lung cancer (NSCLC) in Chicago this month. ... plus docetaxel as a second-line therapy for patients with KRAS mutation-positive, ...
    5-16-2013
  • American Society of Gene & Cell Therapy
    Salt Lake City UT UNITED STATES http://www.asgct.org/meetings-educational-programs/asgct-annual-meetings/2013-annual-meeting
    5-15-2013
  • Moving Genomics Closer to the Clinic
    ... assayed cancer-relevant genes in 24 cases of non-small cell lung cancer (NSCLC). ... was associated with an available treatment or clinical trial of a targeted therapy. ...
    5-15-2013
  • FDA Approves Roche EGFR Mutation CDx for NSCLC
    will allow physicians to identify non-small cell lung cancer patients who are candidates for receiving Tarceva as first-line therapy," said FDA's Alberto Gutierrez, Ph.D., ...
    5-15-2013
  • Softening the Blow from FOLFOX Treatment
    preclinical studies on PledOx and chemotherapies involved with non-small-cell lung cancer. ... Less than half of colorectal cancer patients undergo therapy as intended. "It's more by ...
    5-15-2013
  • Induced Pluripotent Stem Cells: A U.S. Patent Landscape Analysis
    .../diagnostic use, therapy or a device?; (b) types of cells and their use, i.e., in vitro versus in vivo use of iPS cells and the tissue of the originating cell type, e.g., ...
    5-13-2013
  • Lilly Halts Development of Lymphoma Drug After Phase III Failure
    relapse in patients with diffuse large B-cell lymphoma (DLBCL)-the pharma giant's fifth ... not responded adequately to methotrexate therapy, though the company said it was ...
    5-10-2013
  • ATMI Supplies Bioreactor for Orgenesis, Takes $1.3M Stake
    Integrity Xpansion multiplate single-use bioreactor technology was specially developed by ATMI for addressing the scaling-up challenges of cell therapy manufacturing processes. ...
    5-9-2013
  • Companion Diagnostics: 52 Pick-Up
    ... of breast cancer patients for whom Herceptin (trastuzumab) therapy is being considered. ... Gene via FISH in FFPE non-small cell lung cancer (NSCLC) tissue specimens to aid in ...
    5-9-2013
  • The Tumor Microenvironment as a Drug Target, Part II
    ... is FAP (fibroblast activation protein), a cell surface serine protease selectively ... "Existing and future FAP directed therapy may be explored in conjunction with ...
    5-7-2013
  • Analytik Jena Acquires Sepsis Test Among SIRS-Lab Assets
    ... Konrad Reinhart, M.D., director of the Clinic for Anesthesiology and Intensive Therapy ... Hanspeter Saluz, Ph.D., head of the cell and molecular biology department at Jena's ...
    5-6-2013
  • Turning Off Cancer's "Master Regulator"
    ... The next step, Dr. Resar says, is to try to develop a therapy based on that principle. The ... repressed in tumor cells, puts a halt to cell growth and a range of processes needed for ...
    5-3-2013
  • Novartis, Oxford BioMedica Ink Production Agreement for Lentiviral...
    leukemia, B-cell acute lymphocytic leukemia, and diffuse large B-cell lymphoma. ... is expected to raise the gene-based therapy firm's valuation from £58.5 million ($91 ...
    5-1-2013
  • Biomarkers Take Center Stage
    they can be used to diagnose a condition or predict whether a therapy may be successful. ... diseases such as rheumatoid arthritis, psoriatic arthritis, SLE, or giant cell arteritis. ...
    5-1-2013
  • Biologically Relevant Laminins
    ... recombinant laminin-521 in a xeno-free environment is simple to use and can provide a bridge for the gap between academic stem cell research and development of human cell therapy. ...
    5-1-2013
  • More »

    Journal Articles

  • Nonexpanded Mesenchymal Stem Cells for Regenerative Medicine...
    Massimo Faustini, Massimo Bucco, Theodora Chlapanidas, Giulia Lucconi, Mario Marazzi, Marta Cecilia Tosca, Paolo Gaetani, Marco Klinger, Simona Villani, Virginia Valeria Ferretti, Daniele Vigo, Maria Luisa Torre
    Tissue Engineering, Part C: Methods
    These cells are ideal candidates for use in regenerative medicine, tissue engineering, including gene therapy, and cell replacement cancer therapies. In this work, we aimed to the ...
  • Isolation and Characterization of Mesenchymal Stem Cells from...
    Silvia Díaz-Prado, Emma Muiños-López, Tamara Hermida-Gómez, Ma Esther Rendal-Vázquez, Isaac Fuentes-Boquete, Francisco J. de Toro, Francisco J. Blanco
    Tissue Engineering, Part C: Methods
    Introduction: The human amniotic membrane is a highly abundant and readily available tissue that may be useful for regenerative medicine and cell therapy. Aim: To compare two ...
  • Mesenchymal Stem Cell Therapy for Cutaneous Wounds
    Anne M. Hocking
    Advances in Wound Care
    Mesenchymal Stem Cell Therapy for Cutaneous Wounds Advances in Wound Care Background: Mesenchymal stem cell (MSC) treatment of wounds results in accelerated wound closure, ...
  • Cascade ® Autologous System Platelet-Rich Fibrin Matrix in the...
    Sean M. O'Connell, Karen Hessler, Herbert Dardik
    Advances in Wound Care
    These advanced therapies include wound bed preparation agents (negative wound pressure therapy, hyperbaric oxygen), recombinant growth factors, or bioengineered cell therapies. New ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll